EP4054567A4 - Behandlung von lebererkrankungen - Google Patents

Behandlung von lebererkrankungen Download PDF

Info

Publication number
EP4054567A4
EP4054567A4 EP20886094.0A EP20886094A EP4054567A4 EP 4054567 A4 EP4054567 A4 EP 4054567A4 EP 20886094 A EP20886094 A EP 20886094A EP 4054567 A4 EP4054567 A4 EP 4054567A4
Authority
EP
European Patent Office
Prior art keywords
treatment
liver disorders
disorders
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20886094.0A
Other languages
English (en)
French (fr)
Other versions
EP4054567A1 (de
Inventor
Martijn Fenaux
Yujin Wang
Weidong Zhong
Kevin Klucher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terns Pharmaceuticals Inc
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of EP4054567A1 publication Critical patent/EP4054567A1/de
Publication of EP4054567A4 publication Critical patent/EP4054567A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP20886094.0A 2019-11-08 2020-11-06 Behandlung von lebererkrankungen Withdrawn EP4054567A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962933277P 2019-11-08 2019-11-08
US202063004403P 2020-04-02 2020-04-02
PCT/US2020/059522 WO2021092474A1 (en) 2019-11-08 2020-11-06 Treating liver disorders

Publications (2)

Publication Number Publication Date
EP4054567A1 EP4054567A1 (de) 2022-09-14
EP4054567A4 true EP4054567A4 (de) 2024-01-10

Family

ID=75849579

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20886094.0A Withdrawn EP4054567A4 (de) 2019-11-08 2020-11-06 Behandlung von lebererkrankungen

Country Status (11)

Country Link
EP (1) EP4054567A4 (de)
JP (1) JP2023501386A (de)
KR (1) KR20220098168A (de)
CN (1) CN114667142A (de)
AU (1) AU2020380968A1 (de)
BR (1) BR112022008639A2 (de)
CA (1) CA3160445A1 (de)
CL (1) CL2022001167A1 (de)
IL (1) IL292459A (de)
MX (1) MX2022005407A (de)
WO (1) WO2021092474A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3201466A1 (en) 2020-12-14 2022-06-23 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
TW202539702A (zh) * 2024-03-08 2025-10-16 大陸商上海拓界生物醫藥科技有限公司 靶向ＩＮＨＢＥ的ＲＮＡｉ劑

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023245A1 (en) * 2017-07-25 2019-01-31 Cedars-Sinai Medical Center METHODS OF TREATING HEPATIC DISEASES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US20140187633A1 (en) * 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US11419878B2 (en) * 2016-03-28 2022-08-23 Intercept Pharmaceuticals, Inc. Medicine obtained by combining FXR agonist and ARB
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EP3844156A4 (de) * 2018-08-30 2022-06-08 Terns Pharmaceuticals, Inc. Behandlung von lebererkrankungen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023245A1 (en) * 2017-07-25 2019-01-31 Cedars-Sinai Medical Center METHODS OF TREATING HEPATIC DISEASES

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Bile Acids and Their Receptors", vol. 256, 14 June 2019, SPRINGER INTERNATIONAL PUBLISHING, Cham, ISBN: 978-3-030-22005-1, article GEGE CHRISTIAN ET AL: "Nonsteroidal FXR Ligands: Current Status and Clinical Applications", pages: 167 - 205, XP093103470, DOI: 10.1007/164_2019_232 *
ANONYMOUS: "Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting 2019 | Business Wire", 15 October 2019 (2019-10-15), pages 1 - 2, XP093103551, Retrieved from the Internet <URL:https://www.businesswire.com/news/home/20191015005032/en/Terns-Pharmaceuticals-to-Present-Positive-Preclinical-Data-on-FXR-Agonist-TERN-101-at-The-Liver-Meeting -2019> [retrieved on 20231120] *
CARR ROTONYA M ET AL: "FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease", CURRENT ATHEROSCLEROSIS REPORTS, SPRINGER US, NEW YORK, vol. 17, no. 4, 18 February 2015 (2015-02-18), pages 1 - 14, XP035470130, ISSN: 1523-3804, [retrieved on 20150218], DOI: 10.1007/S11883-015-0500-2 *
GENIN MICHAEL J. ET AL: "Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1 H -indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia", JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, no. 24, 14 November 2015 (2015-11-14), US, pages 9768 - 9772, XP055932709, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.5b01161 *
KLUCHER KEVIN ET AL: "FRI-313-A novel farnesoid X receptor agonist, TERN-101, reduces liver steatosis, inflammation, ballooning and fibrosis in a murine model of non-alcoholic steatohepatitis", JOURNAL OF HEPATOLOGY, vol. 70, no. 1, 1 April 2019 (2019-04-01), AMSTERDAM, NL, pages e534, XP093103535, ISSN: 0168-8278, DOI: 10.1016/S0618-8278(19)31056-4 *
See also references of WO2021092474A1 *
YUJIN WANG ET AL: "Pharmacokinetics, Tissue Distribution and Pharmacodynamics of TERN-101, a Novel Farnesoid Xreceptor (FXR) Agonist, in Preclinical Species", HEPATOLOGY; AASLD ABSTRACTS, JOHN WILEY & SONS, INC, US, vol. 70, no. Suppl. 1, 1 October 2019 (2019-10-01), pages 1277, XP009550030, ISSN: 0270-9139 *

Also Published As

Publication number Publication date
CA3160445A1 (en) 2021-05-14
CN114667142A (zh) 2022-06-24
IL292459A (en) 2022-06-01
MX2022005407A (es) 2022-05-24
JP2023501386A (ja) 2023-01-18
CL2022001167A1 (es) 2023-02-10
BR112022008639A2 (pt) 2022-07-19
KR20220098168A (ko) 2022-07-11
WO2021092474A1 (en) 2021-05-14
EP4054567A1 (de) 2022-09-14
AU2020380968A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
IL288001A (en) Compounds for the treatment of neurodegenerative and metabolic disorders
EP3704108A4 (de) Verbindungen und zusammensetzungen zur behandlung von hämatologischen störungen
EP3448398A4 (de) Zusammensetzungen und verfahren zur behandlung von hauterkrankungen
MA52219A (fr) Traitement de l&#39;hidradénite suppurée à l&#39;aide d&#39;inhibiteurs de jak
EP3481387A4 (de) Verfahren und zusammensetzungen zur behandlung von epileptischen erkrankungen
EP3340982A4 (de) Verbindungen zur behandlung von immun- und entzündungserkrankungen
EP3448875A4 (de) Zusammensetzungen zur behandlung einer erkrankung
EP3448987A4 (de) Zusammensetzungen zur behandlung einer erkrankung
EP3328376A4 (de) Verfahren und zusammensetzung zur behandlung metabolischer umprogrammierungserkrankungen
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
EP3328864A4 (de) Therapeutische verbindungen und zusammensetzungen zur behandlung von sozialen störungen und drogenmissbrauch
EP3352749A4 (de) Verbindungen und zusammensetzungen zur behandlung von augenkrankheiten
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
EP3331527A4 (de) Verfahren zur behandlung von entwicklungsstörungen mit pipradrol
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
EP3661553A4 (de) Verfahren und zusammensetzungen zur behandlung von amyloidablagerungskrankheiten
EP3902536A4 (de) Zusammensetzungen und verfahren zur behandlung von neurodegenerativen störungen
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3826650A4 (de) Verfahren zur behandlung von neurologischen erkrankungen
MA53741A (fr) Procédés de traitement de troubles myéloprolifératifs
MA42985A (fr) Traitement de troubles liés à l&#39;acide biliaire
EP3773491A4 (de) Verfahren zur behandlung von apoe4/4-assoziierten erkrankungen
EP3634370A4 (de) Behandlung von hautkrankheiten
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220511

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231212

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 413/12 20060101ALI20231206BHEP

Ipc: C07D 261/08 20060101ALI20231206BHEP

Ipc: A61K 31/4545 20060101ALI20231206BHEP

Ipc: A61K 31/42 20060101AFI20231206BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_63738/2024

Effective date: 20241202

18W Application withdrawn

Effective date: 20241230